









Markets
/
Stocks
/
nasdaq-sclx
/

Scilex Holding Co

SCLX

29.080USD

+3.420+13.33%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

159.87MMarket Cap

LossP/E TTM



Scilex Holding Co

29.080

+3.420+13.33%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

106 / 175

Overall Ranking

374 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

490.000

Target Price

+1809.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 48.79% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 56.59M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 211.62.

Overvalued

The company’s latest PE is -1.02, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.86M shares, decreasing 20.17% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 294.31K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.97, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 9.90M, representing a year-over-year decrease of 39.55%, while its net profit experienced a year-over-year decrease of 129.00%.

Score

Industry at a Glance

Previous score

6.97

Change



Financials

4.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.46

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.90, which is 2666.77% below the recent high of -24.86 and -33567.60% above the recent low of -302.50.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 106/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Scilex Holding Co is 490.00, with a high of 490.00 and a low of 490.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Hold

Current Rating

490.000

Target Price

+1809.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Scilex Holding Co

SCLX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.22, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 30.29 and the support level at 18.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.22

Change

0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.509

Buy

RSI(14)

72.249

Buy

STOCH(KDJ)(9,3,3)

75.423

Neutral

ATR(14)

2.654

High Vlolatility

CCI(14)

147.414

Buy

Williams %R

10.794

Overbought

TRIX(12,20)

2.088

Sell

StochRSI(14)

92.343

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

25.592

Buy

MA10

25.232

Buy

MA20

22.110

Buy

MA50

16.940

Buy

MA100

11.101

Buy

MA200

11.887

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 41.63%, representing a quarter-over-quarter decrease of 7.78%. The largest institutional shareholder is The Vanguard, holding a total of 294.31K shares, representing 4.23% of shares outstanding, with 71.58% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

SCLX Stock Acquisition JV LLC

1.46M

+3399.97%

The Vanguard Group, Inc.

Star Investors

168.51K

BlackRock Institutional Trust Company, N.A.

161.07K

Geode Capital Management, L.L.C.

46.00K

+28.93%

Ji (Henry H)

19.45K

+3398.56%

Rafferty Asset Management LLC

17.72K

UBS Financial Services, Inc.

20.53K

+751.56%

Morgan Stanley & Co. LLC

9.48K

-34.20%

Norges Bank Investment Management (NBIM)

13.65K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.97, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.